FIELD: medicine.
SUBSTANCE: invention relates to medicine, specifically to dentistry, and is intended for qualitative determination of the dental status of a patient with inflammation of the alveolar mucosa. To qualitatively determine the dental status of a patient with inflammation of the alveolar mucosa, the oral fluid of the patient is examined. Oral fluid of the patient is collected before or no earlier than 30 minutes after a patient has had a meal. Said oral fluid is centrifuged at 3,000 rpm for 15 minutes, diluted with physiological saline at a ratio of 1:100, and re-centrifuged at 3,000 rpm for 15 minutes. Oral fluid ready for examination is placed in a cuvette and a standard method for enzyme-linked immunosorbent assay based on monoclonal antibodies with quantitative determination of matrix metalloproteinase 8 (MMP 8) tissue inhibitor of metalloproteinase 2 (TIMP 2) is performed. In the clinical control group, the level of MMP 8 is 16.28–27.28 ng/ml, and TIMP 2 is 5.59–9.31 ng/ml. With MMP 8 content in the amount of 167.2–276.8 ng/ml and TIMP 2 in the amount of 21.9–39.8 ng/ml, gingivitis of the alveolar mucosa is diagnosed. With MMP 8 content in the amount of 55.6–80.4 ng/ml and TIMP 2 in the amount of 12.4–15.3 ng/ml, periodontitis of the alveolar mucosa is diagnosed. Treatment strategy is predicted based on the results of determining the content of said biomarkers in the patient's oral fluid.
EFFECT: use of the invention significantly improves the accuracy of determining the dental status of a patient with inflammation of the alveolar mucosa, significantly increases the sensitivity of differential rapid diagnosis with the achievement of a high probability of identifying processes that determine the dental status of the patient with inflammation of the alveolar mucosa.
3 cl, 6 ex
